The majority with only less intensive/targeted therapy received only 1 salvage regimen 14/16 (88%) vs 10/30 (33%) having intensive salvage (P = 0.001) In comparison to patients administered intensive salvage, the distribution of intermediate vs. unfavorable cytogenetics (P = 0.47), FLT3/NPM1 status (P = 0.22), age ≥60 years (P = 0.31), primary vs. secondary AML at diagnosis (P = 0.14), % BM blasts prior to salvage (P = 0.24), and attainment of response CR/CRi/MLFS (P = 0.72) with greater than 1 salvage (P = 0.30). The gene discussed is FLT3; the disease is acute myeloid leukemia.